MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$11,809K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of short-term investm...
Sales of short-term investments
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Net loss
Accounts payable and accrued lia...
Purchases of short-term investme...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-9,232
-12,345
-7,216
-11,258
Depreciation
87
87
88
89
Stock-based compensation expense
920
1,660
1,261
1,384
Amortization of right-of-use assets
135
134
135
135
Accretion of discounts on short-term investments, net
64
93
158
252
Accounts receivable and unbilled receivable
-2
9
-72
-272
Prepaid expenses and other current assets
-136
-606
911
-1,080
Other assets
83
295
0
148
Accounts payable and accrued liabilities
-3,477
-1,847
940
-1,961
Operating lease liabilities
-189
-186
-178
-175
Net cash used in operating activities
-11,765
-12,288
-5,967
-10,834
Capital expenditures
44
-
0
18
Maturities of short-term investments
11,528
15,826
16,572
19,519
Purchases of short-term investments
1,303
12,569
6,722
9,341
Sales of short-term investments
2,088
-
899
0
Net cash provided by (used in) investing activities
12,269
3,257
10,749
10,160
Proceeds from sale of common stock
212
-
0
-
Proceeds from exercise of warrants, net of expense of 169 and 0, respectively
-
-
2,088
-
Payment of issuance costs
64
-
-
-
Proceeds from exercise of options
1
105
465
25
Net cash provided by financing activities
149
105
2,553
25
Net change in cash and cash equivalents
653
-8,926
7,335
-649
Cash and cash equivalents - beginning of period
8,544
17,470
10,135
51,470
Cash and cash equivalents - end of period
9,197
8,544
17,470
10,135
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of short-term
investments
$11,528K
(-67.08%↓ Y/Y)
Sales of short-term
investments
$2,088K
(68.93%↑ Y/Y)
Proceeds from sale of
common stock
$212K
Proceeds from exercise of
options
$1K
(-66.67%↓ Y/Y)
Net cash provided by
(used in) investing...
$12,269K
(162.70%↑ Y/Y)
Net cash provided by
financing activities
$149K
(4866.67%↑ Y/Y)
Canceled cashflow
$1,347K
Canceled cashflow
$64K
Net change in cash
and cash...
$653K
(101.60%↑ Y/Y)
Canceled cashflow
$11,765K
Purchases of short-term
investments
$1,303K
(-97.66%↓ Y/Y)
Capital expenditures
$44K
(69.23%↑ Y/Y)
Stock-based compensation
expense
$920K
(-69.82%↓ Y/Y)
Prepaid expenses and
other current assets
-$136K
(64.95%↑ Y/Y)
Amortization of right-of-use
assets
$135K
(-50.00%↓ Y/Y)
Depreciation
$87K
(-53.48%↓ Y/Y)
Accounts receivable and
unbilled receivable
-$2K
(99.19%↑ Y/Y)
Payment of issuance
costs
$64K
Net cash used in
operating activities
-$11,765K
(44.30%↑ Y/Y)
Canceled cashflow
$1,280K
Net loss
-$9,232K
(66.28%↑ Y/Y)
Accounts payable and
accrued liabilities
-$3,477K
(-207.88%↓ Y/Y)
Operating lease
liabilities
-$189K
(44.08%↑ Y/Y)
Other assets
$83K
(-75.00%↓ Y/Y)
Accretion of discounts on
short-term investments,...
$64K
(-85.39%↓ Y/Y)
Buy us a coffee
Cardiff Oncology, Inc. (CRDF)
Cardiff Oncology, Inc. (CRDF)